Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Journals » World Heart Journal » Volume 9 Issue 2 Articles » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Central Asia: Perspectives and Present Challenges
$144.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Bestsellers
01.Statin Administration and the Risk of New-Onset Diabetes (pp. 113-120)
02.A Rare Case of Thrombus in Transit through Patent Foramen Ovale: A Burjeel Hospital Case Report (pp. 165-168)
Notifications more
NotificationsNotify me of updates to Statin Administration and the Risk of New-Onset Diabetes (pp. 113-120)
Tell A Friend
 
Tell someone you know about this product.
Statin Administration and the Risk of New-Onset Diabetes (pp. 113-120) $45.00
Authors:  Jan Fedacko, RB Singh, Daniel Pella, Dominik Pella, and Anna Gvozdjakova
Abstract:
There is evidence that long-term use of statins can predispose to new-onset incident diabetes. A recent meta-analysis demonstrated that statin therapy was associated with a risk of incident diabetes. The study showed that relative reduction in low-density lipoprotein cholesterol (LDL-C) was a good indicator of the risk of new-onset diabetes. The overall risk of incident diabetes increased by 11% and the group with intensive LDL-C reduction statin had an 18% increase in the likelihood of developing diabetes. The risks of incident diabetes were 13% and 29% in the subgroups with 3040% and 4050% reductions in LDL-C, respectively. These findings showed that LDL-C decrease may provide a dynamic risk assessment parameter for new-onset diabetes. LDL-C lowering may be positively related to the risk of new-onset diabetes. It is important to perform blood glucose monitoring if there is a 30% decline in LDL cholesterol during lipid lowering therapy, to detect incident diabetes in these populations. However, all statins do not have the same effects: rosuvastatin and atorvastatin administration is more commonly and pitavastatin least commonly associated with diabetes. More studies are required to examine whether intensive therapy with statin can cause new-onset diabetes, which may be due to decreased insulin sensitivity. 


Available Options:
Version:
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2022

Statin Administration and the Risk of New-Onset Diabetes (pp. 113-120)